A lot in the report. I particularly liked this part "With
our strong cash position we are well placed to expand Ryoncil® indications to other serious and life threatening pediatric inflammatory diseases, and to adults with acute GvHD"
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.58 |
Change
0.010(0.64%) |
Mkt cap ! $2.015B | |||
| Open | High | Low | Value | Volume |
| $1.60 | $1.60 | $1.57 | $4.811M | 3.037M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 37 | 48039 | $1.58 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.58 | 58123 | 47 |
View Market Depth
| Last trade - 14.12pm 24/06/2025 (20 minute delay) ? |
| MSB (ASX) Chart |